Darya Bubman | UCSF Profiles

Darya Bubman, PhD

Title	Intellectual Property Officer
Institution	University of California San Francisco
Department	Innovation Ventures
Address	600 16th St San Francisco CA 94158
Phone	415-237-1585
vCard	Download vCard

Overview

Darya joined the Office of Innovation, Technology and Alliances (ITA) in November 2011. Her responsibilities include technology management, licensing and outgoing material transfer agreements. Darya earned a B.A. degree in Biochemistry from Cornell University in Ithaca, N.Y. and a Ph.D. in Pharmacology from the Weill Cornell Graduate School of Medical Sciences in New York City. She conducted her doctoral work in the laboratory of Dr. Ethel Cesarman, studying deregulation of cancer signaling pathways by the Kaposi’s sarcoma-associated herpesvirus (KSHV) in primary effusion lymphoma. Following her graduate studies, Darya became an AAAS Science and Technology Policy Fellow and worked at the U.S. State Department in the Intellectual Property Office on international issues related to biomedical IP, innovation, and technology transfer. Prior to joining the ITA, she worked as a Technology Partnerships Manager at the NASA Ames Research Center located at Moffett Field, CA. Darya has a strong background in virology, oncology, pharmacology and molecular biology.

Darya is passionate about working with UCSF faculty and staff to transfer novel UCSF biomedical technologies from bench to bedside.

ORNG Applications

Websites

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.

List All | Timeline

Czuchlewski DR, Csernus B, Bubman D, Hyjek E, Martin P, Chadburn A, Knowles DM, Cesarman E. Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome. Am J Clin Pathol. 2008 Dec; 130(6):957-62. PMID: 19019774; PMCID: PMC3614404.

View in: PubMed, PubMed Central
Guasparri I, Bubman D, Cesarman E. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood. 2008 Apr 01; 111(7):3813-20. PMID: 18230756; PMCID: PMC2275034.

View in: PubMed, PubMed Central
Bubman D, Guasparri I, Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene. 2007 Jul 26; 26(34):4979-86. PMID: 17310999.

View in: PubMed
Fan W, Bubman D, Chadburn A, Harrington WJ, Cesarman E, Knowles DM. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol. 2005 Jan; 79(2):1244-51. PMID: 15613351; PMCID: PMC538532.

View in: PubMed, PubMed Central
Bubman D, Cesarman E. Pathogenesis of Kaposi's sarcoma. Hematol Oncol Clin North Am. 2003 Jun; 17(3):717-45. PMID: 12852653.

View in: PubMed
Birk AV, Bubman D, Broekman MJ, Robertson HD, Drosopoulos JH, Marcus AJ, Szeto HH. Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biology. J Lab Clin Med. 2002 Feb; 139(2):116-24. PMID: 11919550.

View in: PubMed